Technical Analysis for RGNX - REGENXBIO Inc.

Grade Last Price % Change Price Change
grade D 37.16 2.31% 0.84
RGNX closed up 2.31 percent on Friday, November 15, 2019, on 64 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. It ran into resistance at its 50 day moving average.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical RGNX trend table...

Date Alert Name Type % Chg
50 DMA Resistance Bearish 0.00%
Narrow Range Bar Range Contraction 0.00%
NR7 Range Contraction 0.00%
NR7-2 Range Contraction 0.00%
MACD Bearish Centerline Cross Bearish 2.31%
NR7 Range Contraction 2.31%
Down 3 Days in a Row Weakness 2.31%
Down 4 Days in a Row Weakness 2.31%
20 DMA Resistance Bearish 1.53%
Fell Below 50 DMA Bearish 1.53%

Older signals for RGNX ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
REGENXBIO Inc., a biotechnology company, focuses on the development, commercialization, and licensing of recombinant adeno-associated virus (AAV) gene therapy. The company's development programs include RGX-501, a product candidate for the treatment of homozygous familial hypercholesterolemia, which uses the AAV8 vector to deliver the human low-density lipoprotein receptor gene to liver cells; and RGX-111, a product candidate for the treatment of Mucopolysaccharidosis Type I, which uses the AAV9 vector to deliver the human a-l-iduronidase gene to the central nervous system. Its programs also include RGX-121, a product candidate for the treatment of Mucopolysaccharidosis Type II; RGX-314, a product candidate for the treatment of wet age-related macular degeneration; and RGX-321, a product candidate for the treatment of X-linked retinitis pigmentosa. The company was formerly known as REGENX Biosciences, LLC and changed its name to REGENXBIO Inc. in September 2014. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.
Biotechnology Biology Emerging Technologies Gene Therapy Molecular Biology Genetics Medical Genetics Applied Genetics Wet Age Related Macular Degeneration Retinitis Pigmentosa Gene Delivery Adeno Associated Virus Homozygous Familial Hypercholesterolemia Iduronidase X Linked Retinitis Pigmentosa
Is RGNX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 65.62
52 Week Low 30.38
Average Volume 539,038
200-Day Moving Average 45.3749
50-Day Moving Average 37.482
20-Day Moving Average 37.927
10-Day Moving Average 37.597
Average True Range 2.1674
ADX 10.03
+DI 19.5887
-DI 24.6587
Chandelier Exit (Long, 3 ATRs ) 34.9978
Chandelier Exit (Short, 3 ATRs ) 40.5222
Upper Bollinger Band 41.2315
Lower Bollinger Band 34.6225
Percent B (%b) 0.38
BandWidth 17.425581
MACD Line -0.1054
MACD Signal Line 0.0345
MACD Histogram -0.1399
Fundamentals Value
Market Cap 1.15 Billion
Num Shares 30.9 Million
EPS -2.69
Price-to-Earnings (P/E) Ratio -13.81
Price-to-Sales 99.62
Price-to-Book 4.15
PEG Ratio 1.02
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 38.72
Resistance 3 (R3) 38.67 38.11 38.46
Resistance 2 (R2) 38.11 37.71 38.13 38.37
Resistance 1 (R1) 37.63 37.46 37.87 37.68 38.29
Pivot Point 37.07 37.07 37.19 37.09 37.07
Support 1 (S1) 36.59 36.67 36.83 36.64 36.03
Support 2 (S2) 36.03 36.42 36.05 35.95
Support 3 (S3) 35.55 36.03 35.86
Support 4 (S4) 35.60